cyclic GMP


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

cyclic GMP

[¦sī·klik ¦jē¦em′pē]
(biochemistry)
A 3′,5′-cyclic ester of guanosine monophosphate that is involved in vision transduction through its direct effects on Na+and Ca2+channels in the plasma membrane of rod cells.
Mentioned in ?
References in periodicals archive ?
1984), while SNP, a NO donor, induces vascular smooth muscle relaxation mainly through the activation of the soluble guanylyl cyclase, both pathways leading to the subsequent increase in cyclic GMP levels.
Mice treated with sildenafil showed browning of the white fat after just a few days of treatment, which is believed to be the result of high cyclic GMP levels.
Oxygen radical/nitric oxide mediate calcium-dependent hormone action on cyclic GMP system: a novel concept in signal transduction mechanisms.
Depending on the direction of nitric oxide release and the site of cyclic GMP activation, differing biological effects can be observed.
A small molecule called cyclic GMP has now been recognized by scientists as the crucial messenger chemical in both types of cells that sense light in animals' eyes.
Phosphodiesterases (PDEs) are a family of enzymes that metabolize the intracellular messengers cyclic AMP (cAMP) and cyclic GMP.
Along with his mentor, he demonstrated that nitric oxide and cyclic GMP inhibit smooth muscle and mesangial cell growth and proliferation induced by serum and various growth factors, such as platelet-derived growth factor, epidermal growth factor, insulin-like growth factor, and fibroblast growth factor.
Phosphodiesterases are a family of enzymes that metabolize the intracellular second messengers cyclic AMP (cAMP) and cyclic GMP.
It achieves this selectivity by inhibiting certain cyclic GMP phosphodiesterases that are expressed at high levels in the abnormal cells, thus freeing those damaged cells to die through normal cellular processes.
Patent and Trademark Office generally covering cyclic GMP phosphodiesterase 2 and 5 inhibition to treat inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease.
Research has previously shown that these drugs act by inhibiting certain cellular proteins called cyclic GMP phosphodiesterases (cGMP PDEs) that are overexpressed in a variety of tumor types.

Full browser ?